INT5045

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.62
First Reported 1982
Last Reported 2011
Negated 7
Speculated 2
Reported most in Abstract
Documents 26
Total Number 28
Disease Relevance 7.15
Pain Relevance 11.61

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (VIP)
Anatomy Link Frequency
plasma 2
SH-SY5Y 1
smooth muscle 1
cerebrospinal fluid 1
muscle 1
VIP (Homo sapiens)
Pain Link Frequency Relevance Heat
substance P 73 100.00 Very High Very High Very High
Neuropeptide 49 100.00 Very High Very High Very High
Cholecystokinin 26 100.00 Very High Very High Very High
Somatostatin 13 100.00 Very High Very High Very High
antagonist 10 100.00 Very High Very High Very High
Neurotransmitter 7 100.00 Very High Very High Very High
Pain 7 100.00 Very High Very High Very High
Calcitonin gene-related peptide 28 99.92 Very High Very High Very High
Neuropathic pain 1 99.60 Very High Very High Very High
transcutaneous nerve stimulation 10 99.32 Very High Very High Very High
Disease Link Frequency Relevance Heat
Pain 7 99.84 Very High Very High Very High
Neuroblastoma 4 99.60 Very High Very High Very High
Neuropathic Pain 3 99.60 Very High Very High Very High
Ganglion Cysts 9 99.52 Very High Very High Very High
Achalasia 79 99.40 Very High Very High Very High
Cv Unclassified Under Development 4 98.92 Very High Very High Very High
Dyspepsia 6 98.84 Very High Very High Very High
Rheumatoid Arthritis 7 98.68 Very High Very High Very High
Injury 3 98.12 Very High Very High Very High
Irritable Bowel Syndrome /

Irritable Bowel Syndrome Super

70 98.04 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
A highly sensitive radioimmunoassay system for plasma vasoactive intestinal peptide (VIP) was developed to examine the effect of intraduodenal infusion of HCl or fat on the plasma VIP levels in healthy subjects, and the effect of intramuscular injection of neostigmine in patients with irritable bowel syndrome (IBS).
Spec (examine) Regulation (effect) of VIP in fat associated with spastic colon
1) Confidence 0.62 Published 1985 Journal Hepatogastroenterology Section Abstract Doc Link 4018706 Disease Relevance 0.10 Pain Relevance 0.32
In addition, the influence of vasoactive intestinal polypeptide (VIP) and somatostatin (SOM) on the arteries was investigated.
Regulation (influence) of VIP associated with somatostatin
2) Confidence 0.60 Published 1989 Journal Acta Physiol. Scand. Section Abstract Doc Link 2476911 Disease Relevance 0.07 Pain Relevance 0.72
The distribution of nerve fibres immunoreactive for vasoactive intestinal polypeptide (VIP), substance P (SP), methionine-enkephalin (ENK), calcitonin gene-related peptide (CGRP) and neuropeptide Y (NPY) within the circular muscle layer was examined histochemically in the human pylorus, adjacent antrum and duodenum.
Spec (examined) Regulation (immunoreactive) of VIP in muscle associated with neuropeptide, enkephalin, calcitonin gene-related peptide and substance p
3) Confidence 0.42 Published 1992 Journal Clin. Auton. Res. Section Abstract Doc Link 1283961 Disease Relevance 0 Pain Relevance 0.52
The present results suggest that some of the recently discovered neuropeptides (alpha-CGRP, VIP and Som) could be of importance in the regulation of cardiac contractility in man.
Regulation (regulation) of VIP associated with neuropeptide
4) Confidence 0.39 Published 1987 Journal Eur. J. Pharmacol. Section Abstract Doc Link 2881795 Disease Relevance 0 Pain Relevance 0.62
Neostigmine (12.5 micrograms/kg) produced a significant rise in plasma VIP level, and the plasma VIP response to neostigmine was significantly greater in the IBS group than in the normal group.
Regulation (response) of VIP in plasma associated with spastic colon
5) Confidence 0.27 Published 1985 Journal Hepatogastroenterology Section Abstract Doc Link 4018706 Disease Relevance 0.09 Pain Relevance 0.37
High levels of VIP immunoreactivity were also seen in MAN, HVC, and RA, but this label consisted of fiber and terminals only.
Regulation (immunoreactivity) of VIP associated with rheumatoid arthritis
6) Confidence 0.27 Published 1995 Journal Brain Behav. Evol. Section Abstract Doc Link 7796094 Disease Relevance 0.19 Pain Relevance 0.44
Retinoic acid enhances VIP receptor expression and responsiveness in human neuroblastoma cell, SH-SY5Y.
Regulation (responsiveness) of VIP in SH-SY5Y associated with neuroblastoma
7) Confidence 0.27 Published 1989 Journal FEBS Lett. Section Title Doc Link 2546814 Disease Relevance 0.74 Pain Relevance 0.09
No appreciable change in baseline salivary levels of CGRP and VIP was detected in control subjects.
Neg (No) Regulation (change) of VIP
8) Confidence 0.27 Published 2006 Journal Headache Section Body Doc Link 16412148 Disease Relevance 0 Pain Relevance 0
The putative VIP receptor antagonist, VIP(10-28) (10 microM) did not affect the VIP-induced relaxation nor the NANC relaxation to 10 Hz EFS in the presence of apamin and L-NOARG. 9.
Neg (nor) Regulation (affect) of VIP associated with antagonist
9) Confidence 0.27 Published 1996 Journal J Auton Pharmacol Section Abstract Doc Link 8884460 Disease Relevance 0 Pain Relevance 0.09
Neither propranolol nor indomethacin altered the relaxant effects of VIP or PHM, suggesting a direct effect of these peptides on airway smooth muscle.
Neg (Neither) Regulation (altered) of VIP in smooth muscle
10) Confidence 0.24 Published 1986 Journal J. Appl. Physiol. Section Abstract Doc Link 3781947 Disease Relevance 0 Pain Relevance 0.35
Plasma VIP was unchanged in both acute and chronic ischaemia.
Neg (unchanged) Regulation (unchanged) of Plasma VIP in Plasma associated with cv unclassified under development
11) Confidence 0.24 Published 1986 Journal Clin Physiol Section Abstract Doc Link 2420506 Disease Relevance 0.51 Pain Relevance 0.39
Endogenous mechanisms regulate the magnitude of neurogenic secretion, including enzymes (degrade neurotransmitters), nitric oxide (NO) and vasoactive intestinal peptide (VIP) (regulate stimulated secretion), and muscarinic M2 autoreceptors (inhibit acetylcholine release).
Regulation (regulate) of VIP associated with neurotransmitter
12) Confidence 0.24 Published 2001 Journal Respir Physiol Section Abstract Doc Link 11240157 Disease Relevance 0.06 Pain Relevance 0.27
Endogenous mechanisms regulate the magnitude of neurogenic secretion, including enzymes (degrade neurotransmitters), nitric oxide (NO) and vasoactive intestinal peptide (VIP) (regulate stimulated secretion), and muscarinic M2 autoreceptors (inhibit acetylcholine release).
Regulation (regulate) of VIP associated with neurotransmitter
13) Confidence 0.24 Published 2001 Journal Respir Physiol Section Abstract Doc Link 11240157 Disease Relevance 0.06 Pain Relevance 0.27
Endogenous mechanisms regulate the magnitude of neurogenic secretion, including enzymes (degrade neurotransmitters), nitric oxide (NO) and vasoactive intestinal peptide (VIP) (regulate stimulated secretion), and muscarinic M2 autoreceptors (inhibit acetylcholine release).
Regulation (regulate) of vasoactive intestinal peptide associated with neurotransmitter
14) Confidence 0.24 Published 2001 Journal Respir Physiol Section Abstract Doc Link 11240157 Disease Relevance 0.06 Pain Relevance 0.27
Neonatal capsaicin, at the doses employed in this study, destroyed approximately 70% of CGRP- and tachykinin-immunoreactive sensory axons; whereas 6-hydroxydopamine (6-OHDA) at the doses employed resulted in a complete loss of NPY and tyrosine hydroxylase (TH) immunoreactivity without affecting VIP, CGRP, and tachykinins.
Neg (without) Regulation (affecting) of VIP associated with qutenza and calcitonin gene-related peptide
15) Confidence 0.22 Published 1991 Journal Am. J. Anat. Section Abstract Doc Link 1719791 Disease Relevance 0 Pain Relevance 0.57
No significant change in the VIP level of the cerebrospinal fluid was encountered, although the stimulation evoked rises in finger temperature indicating effectiveness of the stimulation.
Neg (No) Regulation (change) of VIP in finger
16) Confidence 0.22 Published 1984 Journal Gen. Pharmacol. Section Abstract Doc Link 6335447 Disease Relevance 0.17 Pain Relevance 0.50
Failure to influence the VIP level in the cerebrospinal fluid by transcutaneous nerve stimulation in humans.
Regulation (influence) of VIP in cerebrospinal fluid associated with transcutaneous nerve stimulation
17) Confidence 0.22 Published 1984 Journal Gen. Pharmacol. Section Title Doc Link 6335447 Disease Relevance 0.17 Pain Relevance 0.52
After RU 486 treatment, however, there was a tendency towards a decrease of NPY- and VIP-immunoreactivity, and an increase of CGRP-immunoreactivity.
Regulation (immunoreactivity) of VIP associated with calcitonin gene-related peptide
18) Confidence 0.21 Published 1990 Journal Hum. Reprod. Section Abstract Doc Link 1702449 Disease Relevance 0.09 Pain Relevance 0.56
VIP and PACAP: very important in pain?
Regulation (important) of VIP associated with pain and neuropeptide
19) Confidence 0.19 Published 1999 Journal Trends Pharmacol. Sci. Section Title Doc Link 10431211 Disease Relevance 0.85 Pain Relevance 0.93
VIP and somatostatin usually caused a moderate dilatation in the arteries, whereas in the veins, somatostatin was without dilatory effect and the VIP-induced dilatation was irregular.
Regulation (irregular) of VIP in veins associated with somatostatin
20) Confidence 0.17 Published 1987 Journal Peptides Section Abstract Doc Link 3588345 Disease Relevance 0 Pain Relevance 1.19

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox